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ABSTRACT 34 
We report here the first evaluation of isavuconazole for inhibition of A. fumigatus 35 
CYP51 and of sterol biosynthesis in the fungus. Voriconazole and isavuconazole 36 
both bound tightly to recombinant AfCYP51A and AfCYP51B isolated in E. coli 37 
membranes. CYP51 reconstitution assays confirmed AfCYP51A and AfCYP51B 38 
in addition to three AfCYP51A mutants (G54W, L98H and M220K) were strongly 39 
inhibited by both triazoles. Voriconazole bound relatively weakly to purified 40 
HsCYP51 unlike isavuconazole, which bound tightly. However, isavuconazole 41 
was a relatively poor inhibitor of HsCYP51 activity with an IC50 value of 25 µM 42 
which was 55- to 120-fold greater than those observed for the A. fumigatus 43 
CYP51 enzymes, albeit not as poor an inhibitor of HsCYP51 as voriconazole 44 
which gave an IC50 value of 112 µM. Sterol analysis of triazole-treated A. 45 
fumigatus Af293 cells confirmed isavuconazole and voriconazole both inhibited 46 
cellular CYP51 activity with the accumulation of 14-methylated sterol substrates 47 
and depletion of ergosterol levels. Isavuconazole elicited a stronger perturbation 48 
of the sterol composition in Af293 than voriconazole at 0.0125 µg ml-1 indicating 49 
increased potency. However, complementation studies in Saccharomyces 50 
cerevisiae using strains containing AfCYP51A and AfCYP51B indicated 51 
isavuconazole to be equally as effective at inhibiting CYP51 activity as 52 
voriconazole. These in vitro studies suggest isavuconazole is an effective 53 
alternative to voriconazole as an antifungal agent against the target CYP51 in 54 
Aspergillus fumigatus.  55 
 56 
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1.   Introduction 57 
 Mortality associated with invasive fungal disease has increased over the 58 
past four decades, primarily through increasing numbers of cancer patients 59 
undergoing chemotherapy and patients undergoing organ transplantation (1, 2, 60 
reviewed in 3). The majority of the invasive fungal infections observed are 61 
caused by Candida and Aspergillus species with mortality rates being high, 62 
particularly for aspergillosis, reaching up to 90%. In addition, increased incidence 63 
of invasive infections by Cryptococcus species, Fusarium species, Trichosporon 64 
species, Scedosporium species and Mucorales (4, 5) requires antifungal drugs 65 
with broader spectra of activity to combat these infections and to overcome 66 
increasing resistance observed against triazole antifungals in some Candida and 67 
Aspergillus strains.  68 
 Currently available antifungal agents include polyenes, echincandins and 69 
azoles. The polyene amphotericin B is a broad spectrum antifungal but is limited 70 
by intra-venous administration and nephrotoxicity. Echinocandins, such as 71 
caspofungin, have good safety profiles but lack oral formulations, have a 72 
relatively narrow spectrum of activity against Candida and Apsergillus species 73 
and there is increasing resistance to echinocandins amongst certain Candida 74 
species. Triazole antifungals have good safety profiles and remain the most 75 
commonly prescribed antifungal agents to treat fungal infections in the clinic and 76 
amongst outpatients (6, 7). Fluconazole has excellent oral bioavailability and is 77 
primarily effective against yeasts and dimorphic fungi but lacks potency against 78 
filamentous fungi, however, incidence of fluconazole resistance amongst 79 
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Candida species is increasing. More recent azoles, including voriconazole (Fig 80 
1), itraconazole and posaconazole, have a broader spectrum of activity to include 81 
filamentous fungi such as Aspergillus species, with posaconazole extending 82 
activity further against Mucorales. These second generation triazoles, however, 83 
exhibit significant drug interactions and interactions with host liver cytochrome 84 
P450 monooxygenases.  85 
 Isavuconazole (Fig 1) is a new broad-spectrum triazole antifungal with 86 
activity against yeasts, dimorphic fungi, Aspergillus species, molds and 87 
Mucorales (8-11). Isavuconazole has a good safety profile and excellent 88 
pharmacokinetic properties making this triazole particularly effective in treating 89 
invasive fungal infections and is currently recommended for the treatment of 90 
invasive aspergillosis and invasive mucormycosis (12). Isavuconazole is 91 
administered as a water-soluble prodrug isavuconazonium, which is rapidly 92 
cleaved by plasma esterases to release the active drug isavuconazole in situ (13, 93 
14).  94 
 Isavuconazole's mode of action is assumed to be similar to other triazole 95 
antifungals, causing inhibition of sterol 14α-demethylase (CYP51) which is 96 
essential for ergosterol biosynthesis in fungi. However no previous publications 97 
have investigated this in detail. Ergosterol is responsible for the regulation of 98 
membrane integrity, fluidity and permeability. Inhibition of CYP51 leads to the 99 
accumulation of 14α-methylated sterols, which pack more loosely in lipid bilayers 100 
leading to 'leaky' and unstable membranes causing arrested cell growth and 101 
division (15). Isavuconazole appears to be as effective as voriconazole in the 102 
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treatment of invasive aspergillosis but with the advantages of a broader spectrum 103 
of activity, more linear pharmacokinetics, less inter-patient variability, increased 104 
water solubility and fewer CYP enzyme-mediated drug-drug interactions than 105 
voriconazole (8, 9, 16). Isavuconazole displayed similar efficacy against 106 
mucormycosis as amphotericin B (9), supporting the use of isavuconazole as 107 
both a front-line and a salvage treatment for mucormycosis.  108 
 In this study the biochemical mechanism of isavuconazole inhibition of 109 
Aspergillus fumigatus CYP51 isoenzymes A and B (AfCYP51A and AfCYP51B) 110 
was demonstrated for the first time using a combination of ligand binding and 111 
CYP51 inhibition studies with recombinant enzymes and modulation of the sterol 112 
profile of A. fumigatus Af293 at inhibitory concentrations of isavuconazole. In 113 
addition, the in vitro effectiveness of isavuconazole as a sterol 14α-demethylase 114 
inhibitor was compared against voriconazole using recombinant Homo sapiens 115 
CYP51 (HsCYP51), AfCYP51B and AfCYP51A enzymes, including three 116 
prevalent AfCYP51A amino acid substitutions (G54W, L98H and M220) known to 117 
confer azole resistance (17-19). 118 
 119 
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2.   Materials and methods 120 
2.1.  Heterologous expression, isolation and purification of recombinant A. 121 
fumigatus and H. sapiens CYP51 proteins.  122 
 The pCWori+:Δ60HsCYP51 (Δ60-truncation of UniProtKB accession 123 
number Q16850), pCWori+:AfCYP51A (Q4WNT5), pCWori+:AfCYP51A:G54W, 124 
pCWori+:AfCYP51A:L98H, pCWori+:AfCYP51A:M220K and pCWori+:AfCYP51B 125 
(Q96W81) expression constructs were created as previously described (20, 21). 126 
The pCWori+:CYP51 constructs were transformed into competent DH5α E. coli 127 
cells and transformants selected using 0.1 mg/ml ampicillin. Growth and 128 
expression conditions, protein isolation and purification were identical to those 129 
previously reported (20, 21). Previously, Δ60HsCYP51 was shown to have the 130 
same ligand binding properties as the full-length HsCYP51 enzyme (20) and is 131 
therefore referred to as HsCYP51 in this manuscript.  132 
 133 
2.2.   Recombinant CYP51 protein characterization.  134 
 The binding properties of isavuconazole and voriconazole (Fig 1) to A. 135 
fumigatus CYP51s A and B and H. sapiens CYP51 were determined 136 
spectrophotometrically as previously described (20) using quartz split-cuvettes 137 
(light path 4.5 mm). Azole antifungals were progressively titrated against 4 µM 138 
HsCYP51, AfCYP51A and AfCYP51B purified proteins and 1 µM AfCYP51A and 139 
AfCYP51B suspensions in E. coli membranes isolated from the expression 140 
clones diluted with 0.1 M Tris-HCl (pH 8.1) and 20% (wt/vol) glycerol at 22°C. 141 
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Azole saturation curves were constructed from ΔApeak-trough of the resultant 142 
difference spectra versus azole concentration.  143 
 The triazole concentrations that cause 50% inhibition of CYP51 activity 144 
(IC50) were determined using the CYP51 reconstitution assay system previously 145 
described (21). H. sapiens CYP51 assays contained 0.5 µM HsCYP51 and 2 µM 146 
H. sapiens cytochrome P450 reductase (UniProt accession number P16435) 147 
using lanosterol as substrate. A. fumigatus CYP51 assays used 50 µl E. coli 148 
membrane preparations containing 0.5 µM AfCYP51A, G54W:AfCYP51A, 149 
L98H:AfCYP51A, M220K:AfCYP51A or AfCYP51B with 1 µM A. fumigatus 150 
cytochrome P450 reductase (UniProt accession number Q4WM67) and eburicol 151 
as substrate. Azole antifungal agents were added in 2.5 µl DMSO followed by 10 152 
minutes incubation at 37°C prior to assay initiation with 4 mM β-NADPH-Na4. 153 
Incubation times were 4 minutes for HsCYP51 and 15 minutes for AfCYP51A and 154 
AfCYP51B at 37°C. Sterol metabolites were recovered by ethyl acetate 155 
extraction and analyzed by gas chromatography mass spectrometry (section 156 
2.3.).  157 
 158 
2.3.   Sterol composition analysis.  159 
 Spore suspensions of Aspergillus fumigatus Af293 (ATCC MYA-4609, 160 
CBS 101355) were prepared in Tween 80 saline, containing 0.025% (wt/vol) 161 
Tween 80 and 0.8% (wt/vol) NaCl. Spores were used to inoculate Sabouraud 162 
media (final concentration of 1x104 cells/ml) in the absence (DMSO control, 1% 163 
vol/vol) or presence of azole. Voriconazole and isavuconazole stocks were 164 
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prepared in DMSO and added to the media to give a final concentration of 0.125 165 
µg/ml azole and 1% (vol/vol) DMSO. Cultures were incubated at 37°C, 250 rpm 166 
for 48 hours. Mycelia were harvested and non-saponifiable lipids were extracted 167 
as previously described (22). Sterols were derivatized using 0.1ml BSTFA:TMCS 168 
(99:1) and 0.3 ml anhydrous pyridine with heating at 80°C for 2 hours (23). TMS-169 
derivatized sterols were analysed by GC/MS using a Thermo 1300 GC coupled 170 
to a Thermo ISQ mass spectrometer (Thermo Scientific, Loughborough, UK) and 171 
identified with reference to relative retention times, mass ions and fragmentation 172 
spectra. GC/MS data files were analyzed using Xcalibur software (Thermo 173 
Scientific).  174 
 175 
2.4.   Complementation studies in Saccharomyces cerevisae.  176 
 YUG37-pcyp51A and YUG37-pcyp51B constructs in Saccharomyces 177 
cerevisiae (24) were used to assess the relative azole sensitivities of wild-type 178 
AfCYP51A and AfCYP51B towards isavuconazole, voriconazole and 179 
itraconazole. YUG37-pcyp51A and YUG37-pcyp51B cells were grown in 1.34% 180 
yeast nitrogen base without amino acids (Difco), 2% galactose, 2% raffinose, 181 
leucine and tryptophan (both at 100 mg/l) and doxycyclin (5 µg/ml) at 30°C for 72 182 
h as previously described (24). MIC determinations were performed in triplicate 183 
according to the CLSI M27-A2 broth dilution method, except for the use of 184 
doxycyclin induction media to grow the cells used for the 2.5 x 103 cells/ml 185 
inoculums in the microtiter plates. Azole concentrations of 0.001 to 2 µg/ml were 186 
assessed and MIC plates were read visually after 72 h at 30°C. MIC here is 187 
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defined as the minimum drug concentration that causes at least 80% inhibition of 188 
growth. 189 
 190 
2.5.   Data analysis.  191 
 Spectral determinations were made using quartz semi-micro cuvettes with 192 
a Hitachi U-3310 UV/VIS spectrophotometer (San Jose, California). Curve-fitting 193 
of ligand binding data was performed using a rearrangement of the Morrison 194 
equation (25) with the computer program QuantumSoft ProFit (version 6.2.11) 195 
(non-linear regression Levenberg-Marquardt algorithm) to determine Kd values of 196 
the azole-CYP51 complexes. Ligand titrations were performed in triplicate and 197 
mean Kd values with standard deviations calculated.  198 
 IC50 enzyme velocities were calculated from gas chromatogram peak 199 
areas for product and substrate. Velocities were standardized against those 200 
observed in the absence of azole antifungal. IC50 experiments were performed in 201 
duplicate and mean IC50 values and standard deviations calculated.  202 
 Sterol composition of A. fumigatus Af293 was calculated using gas 203 
chromatogram peak areas with mass fragmentation patterns confirming sterol 204 
identification. Mean percentage compositions with standard deviations for each 205 
sterol were calculated from three replicate experiments.  206 
 207 
2.6.   Chemicals.  208 
 All chemicals, unless otherwise stated, were obtained from Sigma 209 
Chemical Company (Poole, UK). Voriconazole was obtained from Discovery Fine 210 
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Chemicals (Bournemouth, UK), Isavuconazole from BOC Sciences (Shirley, New 211 
York) and Growth media, sodium ampicillin, IPTG and 5-aminolevulenic acid from 212 
Foremedium Ltd (Hunstanton, UK). 213 
 214 
215 
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3.   Results 215 
3.1.   Azole ligand binding studies.  216 
 Type II binding spectra were observed between all three CYP51 proteins 217 
and both isavuconazole and voriconazole (Fig 2), yielding a peak at ~428 nm and 218 
a trough at ~412 nm, and indicative of the triazole N-4 nitrogen coordinating as 219 
the sixth ligand with the heme iron (26) to form the low-spin CYP51-azole 220 
complex resulting in a 'red-shift' of the heme Soret peak. Similar spectra were 221 
also observed with E. coli membrane suspensions of AfCYP51A and AfCYP51B, 222 
although the spectra were more ragged, in part due to the increased turbidity 223 
caused by the membrane suspensions. 224 
 Azole saturation curves (Fig 3) confirmed isavuconazole and voriconazole 225 
bound tightly to AfCYP51A and AfCYP51B when isolated in the E. coli membrane 226 
fraction from the expression clones with Kd values of 20 to 60 nM (Table 1). In 227 
contrast, voriconazole and isavuconazole binding to purified AfCYP51A and 228 
AfCYP51B was less tight (Table 1). Voriconazole bound to both purified A. 229 
fumigatus CYP51 isoenzymes with similar affinity (Kd ~1 µM) whilst 230 
isavuconazole bound more tightly to AfCYP51B than AfCYP51A reflected in the 231 
10-fold lower Kd value with AfCYP51B (Table 1). Isavuconazole bound tightly to 232 
HsCYP51 (Kd 68 nM) whereas voriconazole bound less tightly (Kd ~2.3 µM).  233 
 234 
3.2.   Azole inhibition of CYP51 sterol 14α-demethylase activity.  235 
 IC50 determinations for voriconazole and isavuconazole (Fig 4) indicated 236 
both were equally effective at inhibiting the enzyme activity of the three 237 
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AfCYP51A mutations (G54W, L98H and M220K) associated with azole 238 
resistance in A. fumigatus, yielding IC50 values of 0.4 to 0.8 µM, with the only 239 
noticeable difference being slightly higher residual CYP51 activities observed at 240 
high isavuconazole concentrations with the G54W and L98H mutants compared 241 
to voriconazole. Isavuconazole was marginally more effective at inhibiting wild-242 
type AfCYP51A and AfCYP51B than voriconazole (Fig 4), with the isavuconazole 243 
IC50 curves dipping below those for voriconazole, however, the difference in IC50 244 
values were less than two-fold (Table 2). Both voriconazole and isavuconazole 245 
were weak inhibitors of HsCYP51 activity in vitro with 32 µM voriconazole 246 
causing 25% inhibition of CYP51 activity compared to 57% inhibition in the 247 
presence of 32 µM isavuconazole (Fig 4). The 4.5-fold difference in IC50 values 248 
obtained with HsCYP51 reflected the stronger inhibition exhibited by 249 
isavuconazole (Table 2). The apparent selectivity for A. fumigatus CYP51s over 250 
human CYP51 based on IC50 values were 290- to 340-fold and 110- to 120-fold 251 
for voriconazole and isavuconazole, respectively.  252 
 253 
3.3   Sterol composition analysis.  254 
 Aspergillus fumigatus Af293 was grown from spores in the presence of 255 
0.0125 µg/ml (0.0358 µM) voriconazole and 0.0125 µg/ml (0.0286 µM) 256 
isavuconazole and in the absence of azole antifungals (DMSO control) and the 257 
sterol content of the cells extracted and then analyzed. The predominant sterol in 258 
the control sample was ergosterol, comprising nearly 91% of the total sterol 259 
content (Table 3) with only 0.6% eburicol present. Treatment with 0.0125 µg/ml 260 
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voriconazole and isavuconazle both resulted in sharp rises in the relative 261 
abundance of the 14-methylated sterols eburicol and lanosterol, indicative of 262 
CYP51 inhibition in the cells (Table 3). The increased 14-methylated sterol 263 
content was more pronounced in the isavuconazole-treated sample, reaching 264 
34% eburicol and 9% lanosterol, than the voriconazole-treated sample that 265 
contained 20% eburicol and 6% lanosterol. Therefore, isavuconazole appeared 266 
to be a more potent inhibitor of cellular CYP51 activity in strain Af293 than 267 
voriconazole, especially bearing in mind the molar isavuconazole concentration 268 
used was 20% lower than that for voriconazole. Levels of toxic 14-methyl-269 
ergosta-8,24(28)-dien-3,6-diol (22) remained low when cells were grown in 270 
0.0125 µg/ml triazole, comprising just 0.7% and 2.6% of the sterol composition 271 
for isavuconazole- and voriconazole-treated cells, respectively. Cellular 272 
ergosterol depletion, another indicator of CYP51 inhibition, was also evident in 273 
the triazole-treated cells falling from 91% of the sterol composition in the control 274 
cells to 55% and 65% in isavuconazole- and voriconazole-treated cells, 275 
respectively.   276 
 277 
3.4   Complementation studies in Saccharomyces cerevisiae.  278 
 Previously both A. fumigatus CYP51 isoenzymes A and B were found to 279 
complement S. cerevisiae sterol 14α-demethylase function (24) using the 280 
YUG37-pcyp51A and YUG37-pcyp51B constructs. MIC values for fluconazole, 281 
clotrimazole, voriconazole, itraconazole and posaconazole with YUG37-pcyp51A 282 
were 8, 0.016, 0.004, 0.125 and 0.063 µg/ml, respectively, compared to 0.5, 283 
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0.016, 0.004, 0.125 and 0.063 µg/ml for YUG37-pcyp51B (24). The control 284 
construct YUG37-pCTRL gave MIC values of 0.25, 0.016, 0.004, 0.031 and 285 
0.063 µg/ml against fluconazole, clotrimazole, voriconazole, itraconazole and 286 
posaconazole, respectively (24). Therefore AfCYP51A conferred tolerance 287 
towards fluconazole, whilst AfCYP51A and AfCYP51B were equally susceptible 288 
to inhibition by clotrimazole, voriconazole, itraconazole and posaconazole.  289 
 In this study, MIC determinations with voriconazole and itraconazole were 290 
repeated along with MIC determinations for the new triazole antifungal 291 
isavuconazole. MIC values obtained with YUG37-pcyp51A were 0.002, 0.0625 292 
and 0.002 µg/ml for voriconazole, itraconazole and isavuconazole, respectively, 293 
compared with 0.001, 0.0313 and 0.001 µg/ml for YUG37-pcyp51B. Therefore 294 
isavuconazole was equally effective at inhibiting both AfCYP51A and AfCYP51B 295 
as voriconazole and was 300-fold more effective than itraconazole.  296 
 297 
298 
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4.   Discussion 298 
 The type II binding spectra observed between voriconazole and 299 
isavuconazole and the three CYP51 proteins (Fig 2) indicated that the mode of 300 
interaction was the same for both triazoles, namely through the triazole N-4 301 
nitrogen coordinating as the sixth ligand with the heme iron (26). Both triazoles 302 
bound tighter to AfCYP51A and AfCYP51B isolated in the E. coli membrane 303 
fraction from the expression clones than to the purified proteins. The fold-304 
difference in the calculated Kd values between purified and membrane-isolated 305 
proteins with voriconazole were 19- and 25-fold for AfCYP51A and AfCYP51B, 306 
respectively, compared to 39- and 11-fold with isavuconazole (Table 1). This 307 
suggests the enzyme conformation adopted by AfCYP51A and AfCYP51B in free 308 
solution was subtly different to that in a lipid bilayer membrane and is supported 309 
by the observation that CYP51 catalysis was ten-fold higher for A. fumigatus 310 
CYP51 proteins isolated in E. coli membranes (21). The tight triazole binding 311 
observed with the membrane A. fumigatus CYP51 proteins suggested AfCYP51A 312 
and AfCYP51B would be strongly inhibited by both voriconazole and 313 
isavuconazole. This was confirmed by the low IC50 values obtained which were 314 
approximately half the CYP51 concentration and indicative of tight binding 315 
inhibitors (Table 2).  316 
 The Kd value for isavuconazole with HsCYP51 was 34-fold lower than that 317 
obtained for voriconazole, suggesting that isavuconazole would be a stronger 318 
inhibitor of HsCYP51 activity. This was confirmed by the IC50 values obtained 319 
with HsCYP51 (Table 2), however, the degree of inhibition caused by 320 
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isavuconazole was less than expected considering the low Kd value of 68 nM. 321 
AfCYP51A in E. coli membranes had a similar Kd for isavuconazole (61 nM) and 322 
yet the IC50 for isavuconazole was 0.21 µM compared to 25 µM obtained with 323 
HsCYP51 (Table 2). This suggests suspension of HsCYP51 in a lipid bilayer in 324 
the presence of substrate and CPR redox partner weakens in situ isavuconazole 325 
binding. This requires further investigation to ascertain the biophysical and 326 
biochemical mechanisms involved. Therefore initial concerns about the relatively 327 
poor selectivity of isavuconazole for the A. fumigatus CYP51s over the human 328 
homolog based on ligand binding data (1.1- to 3.2-fold differences in Kd) were not 329 
observed when IC50 values were measured (108- to 119-fold differences). For 330 
voriconazole the selectivity for the A. fumigatus CYP51s was 45- to 60-fold based 331 
on Kd and 290- to 340-fold based on IC50 (Table 2), indicating voriconazole was 332 
more selective for A. fumigatus CYP51s over the human homolog than 333 
isavuconazole, albeit with isavuconazole still being a strong inhibitor of A. 334 
fumigatus CYP51 activity in vitro. Azole ligand binding studies provide a useful 335 
preliminary screen for new potential CYP51-inhibitory compounds that contain an 336 
azole functional group, including mechanistic information on the mode of 337 
interaction, but confirmatory CYP51 reconstitution assays are required to 338 
determine in vitro IC50 values for each compound.  339 
 IC50 values obtained for voriconazole and isavuconazole against the 340 
G54W, L98H and M220K proteins were only two-fold greater than the wild-type 341 
AfCYP51A indicating both triazoles strongly inhibited CYP51 activity of all three 342 
mutants, with isavuconazole proving marginally more potent than voriconazole, 343 
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albeit at the expense of slightly increased residual activities at high 344 
isavuconazole concentrations (Fig 4). Therefore, isavuconazole is as effective as 345 
voriconazole in terms of inhibiting AfCYP51A and AfCYP51B activity and is a 346 
strong inhibitor of the CYP51 activity of the AfCYP51A mutants G54W, L98H and 347 
M220K which are often associated with resistance / tolerance to itraconazole and 348 
posaconazole. 349 
 These observations were consistent with the azole phenotypes of G54W 350 
and M220K in which G54W was found to confer resistance to itraconazole (MIC 351 
>16 µg/ml) and posaconazole (MIC >8 µg/ml) but not to voriconazole (MIC 0.25 352 
µg/ml) (17) and M220K to confer resistance to itraconazole (MIC >8 µg/ml), 353 
elevated MIC to posaconazole (MIC 1 to 2 µg/ml compared to 0.06 µg/ml for wild-354 
type) but little increase in resistance to voriconazole (MIC 1 µg/ml) (18). Previous 355 
investigations utilizing recombinant G54W and M220K AfCYP51A proteins have 356 
shown these mutations confer resistance against CYP51 inhibition by 357 
itraconazole and posaconazole and limited tolerance to voriconazole (21). MIC 358 
values for isavuconazole with A. fumigatus strains containing the CYP51A G54W 359 
and M220K substitutions were 0.125 to 0.25 µg/ml and 1 to 4 µg/ml, respectively 360 
(27). As isavuconazole was equally effective at inhibiting the AfCYP51A:G54W 361 
and AfCYP51A:L98H proteins, the observed variability in the isavuconazole MICs 362 
for the AfCYP51A:M220K-containing strains suggest additional resistance 363 
mechanisms were also present.  364 
 The two-fold increase in IC50 values for AfCYP51A:L98H over the wild-365 
type enzyme indicates L98H on its own does not confer the full azole resistance 366 
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phenotype observed with AfCYP51A:TR34/L98H-containing strains. This is in 367 
agreement with previous studies using recombinant AfCYP51A:L98H protein (21) 368 
and with A. fumigatus transformation studies (19) in which both the tandem 369 
repeat and the L98H mutation are required to confer itraconazole resistance (MIC 370 
>16 µg/ml) and elevated MIC against voriconazole (2 µg/ml). MIC values for 371 
isavuconazole with AfCYP51A:TR34/L98H-containing strains are variable at 4 to 372 
>16 µg/ml (27), suggesting other azole resistance mechanisms are also present 373 
in some of these strains. 374 
 The relatively high residual CYP51 activities observed for AfCYP51A:L98H 375 
at 8, 16 and 32 µM voriconazole or isavuconazole suggests the L98H mutation 376 
may confer azole tolerance in a clinical setting by facilitating slow A. fumigatus 377 
growth under prolonged triazole treatment regimens, rather than arresting growth 378 
in strains that possess a wild-type AfCYP51A enzyme. In addition, when the 379 
L98H substitution is coupled to a 5-fold increase in AfCYP51A expression levels 380 
associated with TR34 over the wild-type form (28), this could explain the azole 381 
resistance phenotype observed for TR34/L98H combination. 382 
 The prevalence of the AfCYP51A:TR34/L98H genotype is increasing both 383 
numerically and geographically amongst azole resistant A. fumigatus clinical 384 
isolates (29, 30) and other tandem repeat linked AfCYP51A mutations are 385 
emerging, such as TR46/Y121F/T289A (31), TR34/L98H/S297T/F495I (32) and 386 
TR46/Y121F/M172I/T289A/G448S (28). The emergence of these mutations 387 
suggest A. fumigatus is undergoing a similar process previously observed in 388 
Mycosphaerella graminicola CYP51 in which complex genotypes with multiple 389 
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substitutions have been selected during the changing regimes of azole fungicides 390 
deployed over recent decades with the wild-type CYP51 alleles not seen in some 391 
countries (33).   392 
 Less frequently encountered AfCYP51A mutations that confer azole 393 
resistance include G138C, G138S, Y431C, G434C and G448S. Clinical strains 394 
containing AfCYP51A:G138C/S are resistant to isavuconazole, voriconazole and 395 
itraconazole (MIC 8 to >16 µg/ml) but display variable resistance towards 396 
posaconazole (MIC 1 to >16 µg/ml) (34-36). Similarly, clinical A. fumigatus 397 
strains containing the AfCYP51 substitutions Y431C, G434C and G448S are 398 
resistant against isavuconazole, voriconazole, itraconazole and posaconazole 399 
(34-36). Albarrag et al (34) confirmed that G138C and Y431C conferred 400 
resistance against voriconazole, itraconazole and posaconazole using 401 
complementation studies in S. cerevisae, however, unexpectedly the 402 
AfCYP51A:G434C transformant caused hypersensitivity to azole antifungals. The 403 
molecular basis for azole resistance conferred by the AfCYP51A amino acid 404 
substitutions G138C, G138S, Y431C, G434C and G448S would be of interest for 405 
a future study, especially as these substitutions appear to confer the greatest 406 
resistance towards isavuconazole.  407 
 Sterol composition studies confirmed isavuconazole and voriconazole at 408 
0.0125 µg/ml both inhibited cellular CYP51 activity in A. fumigatus Af293, 409 
characterized by the accumulation of 14-methylated sterols and the depletion of 410 
ergosterol, demonstrating the in situ mode of action of both azoles. 411 
Isavuconazole elicited a stronger response than voriconazole even though the 412 
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molar concentration of isavuconazole was 20% lower, confirming isavuconazole 413 
as a more potent inhibitor of cellular CYP51 activity in this strain. Further A. 414 
fumigatus strains (azole sensitive and azole resistant) will need to be evaluated 415 
to establish whether this observation is strain specific or more general.  416 
 Isavuconazole was generally found to be as effective as voriconazole at 417 
inhibiting the growth of Candida spp. (37-39), as well as Cryptococcus spp. (37, 418 
38), Coccidioides spp. (38), Fusarium spp. (38), and Aspergillus spp. (37, 39) but 419 
less effective than voriconazole at inhibiting Scedosporium spp. growth (38). The 420 
FDA currently licenses isavuconazole for the treatment of invasive aspergillosis 421 
and invasive mucormycosis with a recent clinical study showing isavuconazole to 422 
be non-inferior to voriconazole for the primary treatment of invasive mould 423 
disease along with isavuconazole being well tolerated compared to voriconazole 424 
and with fewer drug-related side effects (8). Isavuconazole exhibits moderate 425 
activity towards Mucorales, whereas few Mucorales isolates could be classified 426 
as susceptible to voriconazole (40). However, direct comparisons of MIC values 427 
across compounds are not readily correlated to clinical effectiveness as factors 428 
such as in vivo bioavailability and pharmacokinetic interactions and stability also 429 
contribute to clinical effectiveness.  430 
 431 
5.   Conclusions 432 
 The biochemical mode of action of isavuconazole has been demonstrated 433 
for the first time both in vitro using recombinant CYP51 enzymes, where 434 
isavuconazole inhibits CYP51 activity through direct coordination of the triazole 435 
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nitrogen atom as the sixth axial ligand to the heme ferric ion, and at a cellular 436 
level by analysis of A. fumigatus sterol composition where isavuconazole inhibits 437 
CYP51 activity resulting in an accumulation of 14-methylated sterols and the 438 
depletion of ergosterol. The molecular mode of action of isavuconazole is 439 
confirmed to be the same as other triazole antifungals. 440 
 Isavuconazole is a good alternative to voriconazole as an inhibitor of A. 441 
fumigatus CYP51 activity and A. fumigatus cellular growth and is an effective 442 
inhibitor of two AfCYP51A mutations (G54W and M220K) that confer tolerance 443 
towards itraconazole and posaconazole. Isavuconazole has the disadvantage of 444 
increased inhibition of human CYP51 activity compared to voriconazole. 445 
However, this is offset by increased bioavailability of isavuconazole, linear 446 
pharmacokinetics, fewer drug interactions and lower reported side effects 447 
compared to voriconazle. 448 
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 613 
Fig. 1. Chemical structures of voriconazole [molecular weight, MW 349] and 614 
isavuconazole [MW 437].  615 
 616 
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 617 
Fig. 2. Type II binding spectra. Type II difference spectra were obtained by the 618 
progressive titration of voriconazole and isavuconazole against 4 µM purified 619 
HsCYP51, AfCYP51A and AfCYP51B proteins and E. coli membrane 620 
suspensions containing 1 µM AfCYP51A and AfCYP51B. All spectral 621 
determinations were performed in triplicate, although only one replicate is shown. 622 
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Fig. 3. Azole ligand saturation curves. Ligand saturation curves for voriconazole 625 
(filled circles) and isavuconazole (hollow circles) were constructed from the type 626 
II difference spectra (Fig 2) and were fitted using a rearrangement of the 627 
Morrison equation for tight ligand binding (25). 628 
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Fig. 4. Azole inhibition profiles. IC50 values for voriconazole (filled circles) and 631 
isavuconazole (hollow circles) were determined using a CYP51 reconstitution 632 
assay system that contained either 0.5 µM HsCYP51, 2 µM HsCPR, 50 µM 633 
DLPC or 0.5 µM A. fumigatus CYP51 proteins isolated in the E. coli membrane 634 
fractions from the expression clones supplemented with 1 µM AfCPR. 635 
Additionally, the relative velocities for HsCYP51 in the presence of 75 and 150 636 
µM voriconazole were 0.565 ±0.056 and 0.432 ±0.007. Relative turnover 637 
numbers of 1.00 equate to mean turnover numbers of 1.06, 1.13, 4.91, 2.47, 638 
1.11, and 11.72 min-1 for AfCYP51A, AfCYP51A:G54W, AfCYP51A:L98H, 639 
AfCYP51A:M220K, AfCYP51B, and HsCYP51, respectively. IC50 experiments 640 
were performed in duplicate with the mean values plotted and standard 641 
deviations presented as error bars. 642 
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Table 1   644 
Kd values for voriconazole and isavuconazole.  645 
_______________________________________________________________ 
 Kd (nM) 
 ____________________________________________________ 
 Proteins Membranes 
 _________________________ _________________________ 
CYP51 Voriconazole Isavuconazole Voriconazole Isavuconazole 
_______________________________________________________________ 
HsCYP51 2290 ±120 68 ±23 - - 
AfCYP51A 980 ±239 2358 ±707 51 ±17 61 ±18 
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Table 2   647 
IC50 values for voriconazole and isavuconazole.  648 
__________________________________________ 
 IC50 (µM) 
 ________________________ 
CYP51 Voriconazole Isavuconazole 
__________________________________________ 
HsCYP51 112 ±27 25 ±2 
AfCYP51A 0.38 ±0.05 a 0.21 ±0.03 
AfCYP51A: G54W 0.80 ±0.09 a 0.45 ±0.08 
AfCYP51A: L98H 0.65 ±0.13 a 0.39 ±0.05 
AfCYP51A: M220K 0.84 ±0.08 a 0.46 ±0.04 
AfCYP51B 0.33 ±0.07 a 0.23 ±0.03 
__________________________________________ 
a  as previously reported by Warrilow et al (21). 649 
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Table 3   651 
Sterol composition of control, voriconazole- and isavuconazole-treated A. 652 
fumigatus Af293.  653 
_________________________________________________________________ 
 Sterol composition (%) 
 ___________________________________________ 







Ergosta-5,8,22-trienol 1.5 (±0.0) 1.0 (±0.0) 1.0 (±0.4) 
Ergosterol 90.8 (±0.5) 64.5 (±0.9) 55.1 (±0.8) 
Methylated ergosta-
trienol 
4.8 (±0.4) 3.5 (±0.3)  
14-methyl-ergosta-
8,24(28)-dien-3,6-diol 
 2.6 (±0.6) 0.7 (±0.1) 
Lanosterol  6.4 (±0.3) 9.2 (±0.1) 
Eburicol 0.6 (±0.1) 19.6 (±0.8) 34.0 (±0.7) 
4,4 dimethyl-ergosta-
8,24-dienol 
1.6 (±0.1) 1.0 (±0.2)  
_________________________________________________________________ 
 654 
